<DOC>
	<DOC>NCT02861196</DOC>
	<brief_summary>This research aims to explore the therapeutic effect of neoadjuvant chemotherapy in muscular invasive bladder cancer of T2-4aN0M0, and the survival effect of combined-modality treatment model，then to clarify the probability of bladder preservation, corresponding cancer specific survival, and the quality of life.</brief_summary>
	<brief_title>Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1. bladder urothelium carcinoma 2. cT24aN0M0 3. life expectancy≥1 year 4. ECOG PS 01 5. have no previously received radiotherapy or chemotherapy 6. have no major organ dysfunction 7. have been provided informed written consent 1. extensive carcinoma in situ or ureter invaded 2. distant metastasis at primary diagnosis or lymphatic metastasis according to clinical diagnosis 3. have severe major organ dysfunction 4. cannot finish treatments because of other severe diseases or life expectance≤6 months 5. exist other malignant tumors 6. have severe coagulation disorders 7. no other trails participated in 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>